Lipocine announces peer-reviewed publication of phase 3 study results for tlando®

Salt lake city , jan. 27, 2022 /prnewswire/ -- lipocine inc. (nasdaq: lpcn), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the peer-reviewed publication of positive phase 3 clinical data from the dosing validation ("dv") study which evaluated the fixed-dose oral testosterone undecanoate, tlando, for the treatment of hypogonadism. as previously disclosed, the dv study met its primary endpoint, with tlando restoring testosterone levels to the normal range in hypogonadal males.
LPCN Ratings Summary
LPCN Quant Ranking